ZA200703888B - Anti-glypican 3 antibody having modified sugar chain - Google Patents
Anti-glypican 3 antibody having modified sugar chainInfo
- Publication number
- ZA200703888B ZA200703888B ZA200703888A ZA200703888A ZA200703888B ZA 200703888 B ZA200703888 B ZA 200703888B ZA 200703888 A ZA200703888 A ZA 200703888A ZA 200703888 A ZA200703888 A ZA 200703888A ZA 200703888 B ZA200703888 B ZA 200703888B
- Authority
- ZA
- South Africa
- Prior art keywords
- glypican
- antibody
- sugar chain
- modified sugar
- modified
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004311356 | 2004-10-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200703888B true ZA200703888B (en) | 2009-11-25 |
Family
ID=36227980
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200703888A ZA200703888B (en) | 2004-10-26 | 2007-05-14 | Anti-glypican 3 antibody having modified sugar chain |
Country Status (20)
Country | Link |
---|---|
US (2) | US7867734B2 (xx) |
EP (1) | EP1816140A4 (xx) |
JP (1) | JP4794457B2 (xx) |
KR (1) | KR101296931B1 (xx) |
CN (1) | CN101068836B (xx) |
AU (1) | AU2005297772B2 (xx) |
BR (1) | BRPI0518279A2 (xx) |
CA (1) | CA2585196C (xx) |
CR (1) | CR9151A (xx) |
HK (1) | HK1110335A1 (xx) |
IL (1) | IL182662A (xx) |
MA (1) | MA29025B1 (xx) |
MX (1) | MX2007004593A (xx) |
NO (1) | NO20072366L (xx) |
NZ (1) | NZ554940A (xx) |
RU (1) | RU2451030C2 (xx) |
TW (1) | TWI468514B (xx) |
UA (1) | UA93488C2 (xx) |
WO (1) | WO2006046751A1 (xx) |
ZA (1) | ZA200703888B (xx) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002338020A1 (en) * | 2002-09-04 | 2004-03-29 | Chugai Seiyaku Kabushiki Kaisha | Antibody against blood-solubilized n-terminal peptide in gpc3 |
EP2228445A1 (en) * | 2003-06-18 | 2010-09-15 | Chugai Seiyaku Kabushiki Kaisha | Fucose Transporter |
DE602005024502D1 (de) * | 2004-07-09 | 2010-12-16 | Chugai Pharmaceutical Co Ltd | Anti-glypican-3-antikörper |
CN102698267B (zh) * | 2004-08-24 | 2017-07-21 | 中外制药株式会社 | 使用抗磷脂酰肌醇蛋白聚糖‑3抗体的辅助疗法 |
EP1816140A4 (en) * | 2004-10-26 | 2009-09-02 | Chugai Pharmaceutical Co Ltd | ANTI-GLYPICAN ANTIBODY 3 MODIFIED SWEET CHAIN |
US20070087005A1 (en) * | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
AU2008275985B2 (en) * | 2007-07-17 | 2013-09-19 | E. R. Squibb & Sons, L.L.C. | Monoclonal antibodies against Glypican-3 |
EP3127921A1 (en) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
WO2009041062A1 (ja) * | 2007-09-28 | 2009-04-02 | Chugai Seiyaku Kabushiki Kaisha | 血漿中動態が改善されたグリピカン3抗体 |
CL2009000647A1 (es) * | 2008-04-04 | 2010-06-04 | Chugai Pharmaceutical Co Ltd | Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto. |
US8583781B2 (en) | 2009-01-28 | 2013-11-12 | Headwater Partners I Llc | Simplified service network architecture |
US8589541B2 (en) | 2009-01-28 | 2013-11-19 | Headwater Partners I Llc | Device-assisted services for protecting network capacity |
JP6130307B2 (ja) | 2011-03-17 | 2017-05-17 | ザ ユニバーシティ オブ バーミンガム | 再指向性免疫療法 |
EP3557260B1 (en) | 2012-12-21 | 2022-05-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy |
TWI693073B (zh) | 2012-12-21 | 2020-05-11 | 日商中外製藥股份有限公司 | 對gpc3標的治療劑療法為有效之患者投與的gpc3標的治療劑 |
US10889842B2 (en) * | 2014-01-16 | 2021-01-12 | Calysta, Inc. | Microorganisms for the enhanced production of amino acids and related methods |
AR100353A1 (es) | 2014-05-08 | 2016-09-28 | Chugai Pharmaceutical Co Ltd | Droga de direccionamiento a glipicano 3 (gpc3) que se administra a un paciente que responde a la terapia con drogas de direccionamiento a gpc3 |
MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
JP7096667B2 (ja) | 2015-07-01 | 2022-07-06 | 中外製薬株式会社 | Gpc3標的治療剤が有効である患者に投与されるgpc3標的治療剤 |
WO2017020812A1 (zh) * | 2015-08-03 | 2017-02-09 | 科济生物医药(上海)有限公司 | 抗磷脂酰肌醇蛋白多糖-3的抗体及其应用 |
KR101796688B1 (ko) | 2015-10-29 | 2017-12-01 | 재단법인 목암생명과학연구소 | 신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물 |
BR112018015259A2 (pt) | 2016-01-27 | 2018-12-18 | Medimmune Llc | métodos para preparação de anticorpos com um padrão de glicosilação definido |
US11767362B1 (en) | 2016-03-15 | 2023-09-26 | Chugai Seiyaku Kabushiki Kaisha | Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies |
WO2018019772A1 (en) | 2016-07-26 | 2018-02-01 | Tessa Therapeutics Pte. Ltd. | Chimeric antigen receptor |
JP7125347B2 (ja) | 2016-08-22 | 2022-08-24 | 中外製薬株式会社 | ヒトgpc3ポリペプチドを発現する遺伝子改変非ヒト動物 |
CN106591371A (zh) * | 2016-11-25 | 2017-04-26 | 哈尔滨百伊生生物科技有限公司 | Cd16a/gpc3双抗慢病毒表达载体及其构建方法和应用 |
EP3684413A1 (en) | 2017-09-20 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent |
MX2021003744A (es) | 2018-10-01 | 2021-06-23 | Adicet Bio Inc | Composiciones y métodos relacionados con linfocitos t gamma delta modificados y no modificados para el tratamiento de tumores sólidos. |
JP2022514262A (ja) | 2018-12-17 | 2022-02-10 | レビトープ リミテッド | 双子型免疫細胞エンゲージャー |
KR20220016452A (ko) * | 2019-05-24 | 2022-02-09 | 엘릭시론 이뮤노테라퓨틱스 (홍콩) 리미티드 | 항-csf1r 항체, il10 융합 단백질, 및 이들의 이용 |
EP4023230A4 (en) | 2019-06-05 | 2023-11-15 | Chugai Seiyaku Kabushiki Kaisha | ANTIBODY CLEAVAGE SITE BINDING MOLECULE |
WO2022171100A1 (zh) * | 2021-02-10 | 2022-08-18 | 江苏先声药业有限公司 | Gpc3人源化抗体及其应用 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0242355A (ja) | 1988-08-02 | 1990-02-13 | Hitachi Constr Mach Co Ltd | 超音波検査装置 |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
JPH04336051A (ja) | 1991-05-10 | 1992-11-24 | Toshiba Corp | 超音波診断装置 |
EP0640094A1 (en) | 1992-04-24 | 1995-03-01 | The Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US5622701A (en) * | 1994-06-14 | 1997-04-22 | Protein Design Labs, Inc. | Cross-reacting monoclonal antibodies specific for E- and P-selectin |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
HUP0001136A3 (en) * | 1997-02-12 | 2002-02-28 | Chugai Pharmaceutical Co Ltd | Remedies for lymphocytic tumors |
US7361336B1 (en) * | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
US7052873B2 (en) * | 1997-10-03 | 2006-05-30 | Chugai Seiyaku Kabushiki Kaisha | Natural human antibody |
JPH11118775A (ja) | 1997-10-09 | 1999-04-30 | Canon Inc | 超音波検査装置 |
US6528624B1 (en) * | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
DE69942021D1 (de) | 1998-04-20 | 2010-04-01 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
DK2270147T4 (da) * | 1999-04-09 | 2020-08-31 | Kyowa Kirin Co Ltd | Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle |
JP3606132B2 (ja) | 1999-10-14 | 2005-01-05 | Jfeエンジニアリング株式会社 | 超音波探傷方法およびその装置 |
JP2002048867A (ja) | 2000-08-07 | 2002-02-15 | Mitsubishi Heavy Ind Ltd | 音響探査装置 |
CN1234769C (zh) | 2000-09-12 | 2006-01-04 | 联合碳化化学及塑料技术公司 | 含有烯化氧共聚物的聚合物复合材料 |
ES2651952T3 (es) | 2000-10-06 | 2018-01-30 | Kyowa Hakko Kirin Co., Ltd. | Células que producen unas composiciones de anticuerpo |
JP4336051B2 (ja) | 2001-01-31 | 2009-09-30 | 株式会社エヌ・ティ・ティ・ドコモ | 無線通信端末、発呼制限方法及びプログラム |
US20030003097A1 (en) | 2001-04-02 | 2003-01-02 | Idec Pharmaceutical Corporation | Recombinant antibodies coexpressed with GnTIII |
DE60237929D1 (de) * | 2001-06-22 | 2010-11-18 | Chugai Pharmaceutical Co Ltd | Zellproliferationshemmer, die Anti-Glypican 3 Antikörper enthalten |
EP1423510A4 (en) * | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES |
JP3961359B2 (ja) | 2002-07-18 | 2007-08-22 | 株式会社東芝 | 超音波画像化装置 |
JP4087098B2 (ja) | 2001-11-14 | 2008-05-14 | 株式会社東芝 | 超音波検査装置 |
CN100460872C (zh) * | 2001-11-14 | 2009-02-11 | 株式会社东芝 | 超声波成像装置 |
EP3604523A1 (en) * | 2001-12-28 | 2020-02-05 | Chugai Seiyaku Kabushiki Kaisha | Method for stabilizing proteins |
US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US7662925B2 (en) * | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8188231B2 (en) * | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
EP1498491A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA |
BRPI0311233B8 (pt) * | 2002-05-23 | 2021-07-27 | Sunnybrook And Womens College Health Sciences Centre | métodos in vitro para triagem de um paciente para carcinoma hepatocelular (hcc), e para diagnosticar hcc em um paciente, bem como método e kit para detectar ou determinar o nível de gpc3 em uma amostra |
AU2003254950A1 (en) | 2002-08-26 | 2004-03-11 | Kirin Beer Kabushiki Kaisha | Peptides and drugs containing the same |
AU2002338020A1 (en) * | 2002-09-04 | 2004-03-29 | Chugai Seiyaku Kabushiki Kaisha | Antibody against blood-solubilized n-terminal peptide in gpc3 |
AU2002330482A1 (en) | 2002-09-04 | 2004-03-29 | Perseus Proteomics Inc. | Method of diagnosing cancer by detecting gpc3 |
WO2004022595A1 (ja) | 2002-09-04 | 2004-03-18 | Chugai Seiyaku Kabushiki Kaisha | MRL/lprマウスを用いた抗体の作製 |
US20090010920A1 (en) * | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
JPWO2005023301A1 (ja) * | 2003-09-04 | 2006-11-02 | 中外製薬株式会社 | 胆管癌治療剤および検出薬 |
ITBO20040008U1 (it) | 2004-02-03 | 2004-05-03 | Tonazzi S R L | Macchina per il riempimento e la chiusura di tubetti |
DE602005024502D1 (de) * | 2004-07-09 | 2010-12-16 | Chugai Pharmaceutical Co Ltd | Anti-glypican-3-antikörper |
ATE484288T1 (de) * | 2004-08-08 | 2010-10-15 | Eli Khayat | Pharmazeutische zusammensetzungen zur linderung von übermässig hohen zuckerspiegeln bei diabetikern |
AU2005277567A1 (en) * | 2004-08-16 | 2006-03-02 | Medimmune, Llc | Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity |
CN102698267B (zh) * | 2004-08-24 | 2017-07-21 | 中外制药株式会社 | 使用抗磷脂酰肌醇蛋白聚糖‑3抗体的辅助疗法 |
EP1816140A4 (en) | 2004-10-26 | 2009-09-02 | Chugai Pharmaceutical Co Ltd | ANTI-GLYPICAN ANTIBODY 3 MODIFIED SWEET CHAIN |
US20090061485A1 (en) * | 2004-12-22 | 2009-03-05 | Chugai Seiyaku Kabushiki Kaisha | Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited |
US20070087005A1 (en) | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
EP3127921A1 (en) * | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
BRPI0909672B1 (pt) * | 2008-03-17 | 2018-09-18 | Chugai Pharmaceutical Co Ltd | método de imunoensaio in vitro para detecção da presença de células de câncer de fígado em um indivíduo, método para classificação de células de câncer de fígado presentes em um indivíduo, método in vitro para determinação de administrar ou não um agente anticâncer contendo um anticorpo anti-glipicano 3 a um indivíduo, e método in vitro para determinação de uma dose de um agente anticâncer contendo um anticorpo anti-glipicano 3 no tratamento de câncer de fígado em um indivíduo |
CL2009000647A1 (es) * | 2008-04-04 | 2010-06-04 | Chugai Pharmaceutical Co Ltd | Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto. |
-
2005
- 2005-10-26 EP EP05800031A patent/EP1816140A4/en not_active Ceased
- 2005-10-26 TW TW94137496A patent/TWI468514B/zh not_active IP Right Cessation
- 2005-10-26 US US11/577,944 patent/US7867734B2/en not_active Expired - Fee Related
- 2005-10-26 CN CN2005800368760A patent/CN101068836B/zh not_active Expired - Fee Related
- 2005-10-26 UA UAA200705812A patent/UA93488C2/uk unknown
- 2005-10-26 CA CA2585196A patent/CA2585196C/en not_active Expired - Fee Related
- 2005-10-26 JP JP2006542382A patent/JP4794457B2/ja not_active Expired - Fee Related
- 2005-10-26 BR BRPI0518279-4A patent/BRPI0518279A2/pt not_active IP Right Cessation
- 2005-10-26 RU RU2007119579/10A patent/RU2451030C2/ru not_active IP Right Cessation
- 2005-10-26 NZ NZ554940A patent/NZ554940A/en not_active IP Right Cessation
- 2005-10-26 AU AU2005297772A patent/AU2005297772B2/en not_active Ceased
- 2005-10-26 KR KR1020077011403A patent/KR101296931B1/ko not_active IP Right Cessation
- 2005-10-26 MX MX2007004593A patent/MX2007004593A/es active IP Right Grant
- 2005-10-26 WO PCT/JP2005/020057 patent/WO2006046751A1/ja active Application Filing
-
2007
- 2007-04-19 IL IL182662A patent/IL182662A/en not_active IP Right Cessation
- 2007-05-09 NO NO20072366A patent/NO20072366L/no not_active Application Discontinuation
- 2007-05-14 ZA ZA200703888A patent/ZA200703888B/xx unknown
- 2007-05-17 MA MA29912A patent/MA29025B1/fr unknown
- 2007-05-25 CR CR9151A patent/CR9151A/es not_active Application Discontinuation
-
2008
- 2008-04-23 HK HK08104536.5A patent/HK1110335A1/xx not_active IP Right Cessation
-
2010
- 2010-08-09 US US12/852,950 patent/US20110033452A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2006046751A1 (ja) | 2006-05-04 |
NO20072366L (no) | 2007-06-21 |
AU2005297772A1 (en) | 2006-05-04 |
IL182662A (en) | 2014-09-30 |
BRPI0518279A2 (pt) | 2008-11-11 |
EP1816140A1 (en) | 2007-08-08 |
KR20070070222A (ko) | 2007-07-03 |
HK1110335A1 (en) | 2008-07-11 |
CN101068836A (zh) | 2007-11-07 |
TWI468514B (zh) | 2015-01-11 |
CR9151A (es) | 2008-03-18 |
JP4794457B2 (ja) | 2011-10-19 |
US20110033452A1 (en) | 2011-02-10 |
AU2005297772B2 (en) | 2011-06-23 |
CN101068836B (zh) | 2013-08-14 |
MA29025B1 (fr) | 2007-11-01 |
KR101296931B1 (ko) | 2013-08-14 |
TW200621980A (en) | 2006-07-01 |
IL182662A0 (en) | 2007-09-20 |
RU2451030C2 (ru) | 2012-05-20 |
CA2585196A1 (en) | 2006-05-04 |
EP1816140A4 (en) | 2009-09-02 |
US7867734B2 (en) | 2011-01-11 |
US20080124330A1 (en) | 2008-05-29 |
CA2585196C (en) | 2015-01-06 |
JPWO2006046751A1 (ja) | 2008-05-22 |
NZ554940A (en) | 2010-04-30 |
RU2007119579A (ru) | 2008-12-10 |
UA93488C2 (uk) | 2011-02-25 |
MX2007004593A (es) | 2007-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200703888B (en) | Anti-glypican 3 antibody having modified sugar chain | |
HK1218126A1 (zh) | 抗體 | |
GB0228210D0 (en) | Single chain antibodies | |
IL227753A0 (en) | A qualified antibody or antibody residue | |
PT1599504E (pt) | Anticorpo modificado | |
IL181575A0 (en) | Anti-ox40l antibodies | |
IL228032A0 (en) | Antibodies | |
IL175710A0 (en) | Anti-mpl antibody | |
IL179672A0 (en) | Anti-cd3 antibodies | |
HK1093873A1 (en) | Slide fastener chain | |
IL187106A (en) | Sclerostin binds antibody | |
GB2420392B (en) | Silent chain | |
IL187316A0 (en) | Anti-interleukin 2 antibodies | |
GB0503546D0 (en) | Antibody | |
HK1084839A1 (en) | Bracelet fastener | |
GB0420466D0 (en) | Anti-glucan antibodies | |
ZA200701952B (en) | Anti-OX40L antibodies | |
GB2417997B (en) | Link chain | |
EP1789777A4 (en) | NANOMETRIC MASS TRANSPORTERS | |
EP1780221A4 (en) | ANTI-SYNOVIOLIN ANTIBODY | |
GB0306618D0 (en) | Antibody | |
GB0418415D0 (en) | Antibody | |
GB0420771D0 (en) | Antibody | |
HK1209139A1 (en) | Modified antibody | |
GB0417434D0 (en) | Adaptable necklace |